Multi center clinical intervention study of HMB combined with Lactobacillus plantarum p-8 to accelerate the late rehabilitation of ICU-AW patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040738

Enrollment

Unknown

Registered

2020-12-08

Start date

2020-12-31

Completion date

Unknown

Last updated

2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU acquired weakness

Interventions

control:diet consult

intervention :Diet consult + HMB 3g / D (feeding in 3 times) + Lactobacillus plantarum p-8 2 pieces / day (containing 30 billion active probiotics in total)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) During the ICU in-hospital saty, the diagnosis of ICU-AW was clear, and the ICU was transferred to the rehabilitation department of the research institution for further observation and treatment; (2) Aged between 18 and 65 years old; (3) the planned hospitalization period was more than 3 months, and continuous follow-up was conducted after discharge; (4) voluntary participation in the study.

Exclusion criteria

Exclusion criteria: (1) There are various bone metabolism or muscle diseases, such as myasthenia gravis; (2) accompanied with tumor or type I diabetes, ckd4-5 stage of basic diseases, and severe liver disease; (3) family members of patients refused to participate in the study; (4) unable to eat by mouth or tube feeding; (5) accompanied by intestinal diseases affecting digestion, absorption, metabolism or excretion; or Factors; (6) accompanied by thyroid dysfunction or endocrine or metabolic diseases; (7) pregnant or lactating women; (8) history of mental illness; (9) previous history of allergy to drugs known to be used; (10) previous diarrhea, constipation, or intestinal inflammation; (11) use of probiotics, prebiotics and synbiotics two weeks before enrollment; (12) use of antibiotics Interruption or intestinal fungal infection.

Design outcomes

Primary

Measure	Time frame
Skeletal muscle mass of limbs (BIA method);MRC scoring;Intestinal flora (Bifidobacterium / Enterobacter Kobe value);	—

Secondary

Measure	Time frame
albumin;pre-albumin;globulin;Retinol binding protein,;transferrin;blood creatinine;TNF-ALFA;IL-1;IL-6;CRP;Urea nitrogen;endogenous creatinine clearance rate;daily average blood glucose;Quality of life;ALT;AST;	—

Countries

China

Contacts

Public ContactFu-xiang Li, Ning Lin

The General Hospital of Western Command Theater of PLA

525845176@qq.com+86 13980074996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026